Company intelligence / Profile preview

Canbex Therapeutics Ltd

London, England, United Kingdomuclb.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Completed a Phase 2 Proof of Concept, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and pharmacokinetics of VSN16R for the treatment of spasticity in subjects with multiple sclerosis. The study began in August 2015.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

VSN16R

Phase 1

Indications: Multiple sclerosis spasticity

Partnerships

Fast Forward LLC (National Multiple Sclerosis Society's subsidiary)Ipsen (option agreement)

Beyond the preview

Go deeper on Canbex Therapeutics Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canbex Therapeutics Ltd.

Explore the full profile